Everolimus-eluting stents in interventional cardiology

Bare metal stents have a proven safety record, but limited long-term efficacy due to in-stent restenosis. First-generation drug-eluting stents successfully countered the restenosis rate, but were hampered by concerns about their long-term safety. Second generation drug-eluting stents have combined t...

Descripción completa

Detalles Bibliográficos
Autores principales: Townsend, Jacob C, Rideout, Phillip, Steinberg, Daniel H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3402052/
https://www.ncbi.nlm.nih.gov/pubmed/22910420
http://dx.doi.org/10.2147/VHRM.S23388
_version_ 1782238695495041024
author Townsend, Jacob C
Rideout, Phillip
Steinberg, Daniel H
author_facet Townsend, Jacob C
Rideout, Phillip
Steinberg, Daniel H
author_sort Townsend, Jacob C
collection PubMed
description Bare metal stents have a proven safety record, but limited long-term efficacy due to in-stent restenosis. First-generation drug-eluting stents successfully countered the restenosis rate, but were hampered by concerns about their long-term safety. Second generation drug-eluting stents have combined the low restenosis rate of the first generation with improved long-term safety. We review the evolution of drug-eluting stents with a focus on the safety, efficacy, and unique characteristics of everolimus-eluting stents.
format Online
Article
Text
id pubmed-3402052
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-34020522012-07-30 Everolimus-eluting stents in interventional cardiology Townsend, Jacob C Rideout, Phillip Steinberg, Daniel H Vasc Health Risk Manag Review Bare metal stents have a proven safety record, but limited long-term efficacy due to in-stent restenosis. First-generation drug-eluting stents successfully countered the restenosis rate, but were hampered by concerns about their long-term safety. Second generation drug-eluting stents have combined the low restenosis rate of the first generation with improved long-term safety. We review the evolution of drug-eluting stents with a focus on the safety, efficacy, and unique characteristics of everolimus-eluting stents. Dove Medical Press 2012 2012-06-27 /pmc/articles/PMC3402052/ /pubmed/22910420 http://dx.doi.org/10.2147/VHRM.S23388 Text en © 2012 Townsend et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Townsend, Jacob C
Rideout, Phillip
Steinberg, Daniel H
Everolimus-eluting stents in interventional cardiology
title Everolimus-eluting stents in interventional cardiology
title_full Everolimus-eluting stents in interventional cardiology
title_fullStr Everolimus-eluting stents in interventional cardiology
title_full_unstemmed Everolimus-eluting stents in interventional cardiology
title_short Everolimus-eluting stents in interventional cardiology
title_sort everolimus-eluting stents in interventional cardiology
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3402052/
https://www.ncbi.nlm.nih.gov/pubmed/22910420
http://dx.doi.org/10.2147/VHRM.S23388
work_keys_str_mv AT townsendjacobc everolimuselutingstentsininterventionalcardiology
AT rideoutphillip everolimuselutingstentsininterventionalcardiology
AT steinbergdanielh everolimuselutingstentsininterventionalcardiology

Ejemplares similares